Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.76 |
| ▸ | TSPO | P30536 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | BAX | Q07812 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407885 | 0.89 | DNM1 (0.73) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL407490 | 0.87 | TSPO (0.70) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL410581 | 0.86 | DNM1 (0.77) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL29391692 | 0.86 | DNM1 (1.00) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL29351340 | 0.86 | DNM1 (1.00) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL410147 | 0.86 | DNM1 (1.00) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL18721786 | 0.86 | DNM1 (0.76) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL16923530 | 0.86 | DNM1 (0.62) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL407526 | 0.85 | TSPO (0.77) | DNM1TSPOMAPTSMN1; SMN2HTT | |
| SCHEMBL406252 | 0.85 | TSPO (0.77) | DNM1TSPOMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | claimed |
| EP-2590647-B1 | PRO-NEUROGENIC COMPOUNDS | UNIV TEXAS (US) | 2017-11-08 | — | — | EP | claimed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | claimed |
| US-20160362372-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-12-15 | — | — | US | claimed |
| US-20160206596-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-07-21 | — | — | US | claimed |
| US-20160206594-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-21 | — | — | US | claimed |
| US-20150290195-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-15 | — | — | US | claimed |
| EP-2925129-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2015-10-07 | — | — | EP | claimed |
| US-20150057301-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | claimed |
| US-20140343018-A1 | Anti-depression Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-11-20 | — | — | US | claimed |
| US-20130184301-A1 | Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | claimed |
| EP-2590647-A2 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2013-05-15 | — | — | EP | claimed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | claimed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | claimed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | claimed |
| EP-2385829-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2011-11-16 | — | — | EP | claimed |
| US-8039041-B2 | Electroluminescent devices with electrode protection | CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) | 2011-10-18 | — | — | US | claimed |
| US-20110015217-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-20 | — | — | US | claimed |
| US-20110003836-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-06 | — | — | US | claimed |
| WO-2010081115-A1 | PRO-NEUROGENIC COMPOUNDS | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2010-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184301-A1 | Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds | BDNF, GAP43, DCX | DNM1 1086/4885TSPO 478/4885MAPT 578/4885 |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BDNF, GAP43, DCX | DNM1 897/4885TSPO 2470/4885MAPT 136/4885 |
| US-20160206594-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | DNM1 510/4885TSPO 826/4885MAPT 559/4885 |
| US-20150057301-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | DNM1 625/4885TSPO 671/4885MAPT 620/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | DNM1 897/4885TSPO 2470/4885MAPT 136/4885 |
| US-20110015217-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | DNM1 510/4885TSPO 826/4885MAPT 559/4885 |
| US-20150290195-A1 | PRO-NEUROGENIC COMPOUNDS | DCX, GAP43, BDNF | DNM1 510/4885TSPO 826/4885MAPT 559/4885 |
| US-20140343018-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | DNM1 638/4885TSPO 2600/4885MAPT 142/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | DNM1 897/4885TSPO 2470/4885MAPT 136/4885 |
| US-20110003836-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | DNM1 538/4885TSPO 794/4885MAPT 571/4885 |
| US-20160362372-A1 | PRO-NEUROGENIC COMPOUNDS | DCX, GAP43, BDNF | DNM1 510/4885TSPO 826/4885MAPT 559/4885 |
| US-20160206596-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | DNM1 638/4885TSPO 2600/4885MAPT 142/4885 |
| US-20170157092-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | DNM1 638/4885TSPO 2600/4885MAPT 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.